---
figid: PMC4623479__kcbt-16-01-987093-g006
figtitle: Wnt pathway activation and ABCB1 expression account for attenuation of Proteasome
  inhibitor-mediated apoptosis in multidrug-resistant cancer cells
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC4623479
filename: kcbt-16-01-987093-g006.jpg
figlink: /pmc/articles/PMC4623479/figure/f0006/
number: F6
caption: (A)proposed mechanism of attenuated Proteasome Inhibitor-induced cytotoxicity
  in the multidrug-resistant MES-SA/Dx5 cancer cells Since MES-SA/Dx5 and the parental
  MES-SA cancer cells both trigger similar apoptosis pathway after MG132 or bortezomib
  treatment, MES-SA/Dx5 cells efflux MG132 or bortezomib out of the cell via ABCB1
  expression, resulting in reduced MG132 or bortezomib cytotoxicity. MES-SA/Dx5 cells
  then increase the expression of the cancer-cell growth factors cyclin D1 and c-Myc
  through the Wnt pathway to subsequently inhibit p21 regulation on the cell cycle.
  These events render MES-SA/Dx5 cells capable of resisting cell cycle suspension
  in the G2 phase caused by MG132 or bortezomib, permitting the cancer cells to proliferate
  normally and consequently alleviating proteasome Inhibitor cytotoxicity.
papertitle: Wnt pathway activation and ABCB1 expression account for attenuation of
  Proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells.
reftext: Kowit Yu Chong, et al. Cancer Biol Ther. 2015 Jan;16(1):149-159.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9736857
figid_alias: PMC4623479__F6
figtype: Figure
redirect_from: /figures/PMC4623479__F6
ndex: 8a4b3407-dec1-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4623479__kcbt-16-01-987093-g006.html
  '@type': Dataset
  description: (A)proposed mechanism of attenuated Proteasome Inhibitor-induced cytotoxicity
    in the multidrug-resistant MES-SA/Dx5 cancer cells Since MES-SA/Dx5 and the parental
    MES-SA cancer cells both trigger similar apoptosis pathway after MG132 or bortezomib
    treatment, MES-SA/Dx5 cells efflux MG132 or bortezomib out of the cell via ABCB1
    expression, resulting in reduced MG132 or bortezomib cytotoxicity. MES-SA/Dx5
    cells then increase the expression of the cancer-cell growth factors cyclin D1
    and c-Myc through the Wnt pathway to subsequently inhibit p21 regulation on the
    cell cycle. These events render MES-SA/Dx5 cells capable of resisting cell cycle
    suspension in the G2 phase caused by MG132 or bortezomib, permitting the cancer
    cells to proliferate normally and consequently alleviating proteasome Inhibitor
    cytotoxicity.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MYC
  - CTNNB1
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - PARP1
  - COL11A2
  - PARP2
  - PARP3
  - PARP4
  - PARP6
  - PARP8
  - PARP9
  - PARP10
  - PARP11
  - PARP12
  - PARP14
  - PARP15
  - PARP16
  - TNKS
  - TNKS2
  - TIPARP
  - TP53
  - TP63
  - TP73
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - CASP1
  - CASP2
  - CASP4
  - CASP5
  - CASP6
  - CASP8
  - CASP9
  - CASP10
  - CASP12
  - CASP14
  - CASP3
  - CASP7
  - WARS1
  - Myc
  - arm
  - Wnt5
  - Wnt4
  - wg
  - Wnt2
  - es
  - Parp
  - p53
  - betaTub60D
  - hth
  - dap
  - anon-70Dc
  - Doxorubicin
---
